Vaccine Research

GeoVax's GEO-CM04S1 Shows Superior Immune Response in CLL Patients Compared to mRNA Vaccines

GeoVax's GEO-CM04S1 Shows Superior Immune Response in CLL Patients Compared to mRNA Vaccines

GeoVax Labs, Inc. reports that its GEO-CM04S1 vaccine has demonstrated superior T cell responses in chronic lymphocytic leukemia (CLL) patients compared to an authorized mRNA COVID-19 vaccine, highlighting potential advancements in protecting immunocompromised individuals.

June 17, 2025
Legal Notice Calls for Investigation into COVID-19 Origins and Vaccine Technologies

Legal Notice Calls for Investigation into COVID-19 Origins and Vaccine Technologies

Dr. Leonard G. Horowitz has issued a legal notice urging a thorough investigation into the origins of COVID-19 and the technologies used in vaccine development, highlighting concerns over potential health risks and the need for transparency.

June 10, 2025